Online Thinking Training and Mindfulness for Children After Treatment for Acute Lymphoblastic Leukemia
Tests online cognitive training and mindfulness in children treated for acute lymphoblastic leukemia.
Plain-language title generated from the registry record
Registry title: Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy
Key facts
- Where
- Madrid, SpainSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and teenagers with acute B-cell lymphoblastic leukemia who were treated before. It tests online brain training and mindfulness.
- Age
- 8 to 18 years
- Sex
- All sexes can join.
- Disease stage
- Acute B-cell lymphoblastic leukemia.
- Earlier treatment
- Must have had CAR-T therapy, chemotherapy, and/or hematopoietic stem cell transplantation.
Main reasons for not taking part
- Intellectual disability, autism spectrum disorder, or acquired brain injury
- Uncontrolled or unstable medical or psychiatric conditions unrelated to leukemia
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 8 and 18 years old?
Source: NCT07479927, who can take part
Where in Spain
- Hospital Universitario La PazMadrid, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Hospital Universitario La Paz
- Trial code
- NCT07479927
- Record updated
- 18 March 2026
- Original description
This randomized controlled clinical trial evaluates neurocognitive, biopsychological, and brain connectome outcomes in children and adolescents with acute lymphoblastic leukemia who have previously received Chimeric Antigen Receptor T-cell therapy (CAR T-cell therapy), chemotherapy, and/or hematopoietic stem cell transplantation (HSCT).Read full original descriptionShow less
Randomized Controlled Clinical Trial of Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy. The PsyCARTkids Project
This randomized controlled clinical trial evaluates neurocognitive, biopsychological, and brain connectome outcomes in children and adolescents with acute lymphoblastic leukemia who have previously received Chimeric Antigen Receptor T-cell therapy (CAR T-cell therapy), chemotherapy, and/or hematopoietic stem cell transplantation (HSCT).
Participants will receive a multimodal, telematic psychological intervention combining digital cognitive training and an adapted mindfulness-based emotional regulation program. Outcomes will be compared with a waitlist control group and intervention sequences will be counterbalanced: (1) cognitive training followed by mindfulness; and (2) mindfulness followed by cognitive training.
Neurocognitive performance, emotional-behavioral functioning, executive functioning and EEG-based functional connectivity will be assessed at baseline, post-intervention and at 6 months follow-up.
Inclusion: Diagnosis of acute B-cell lymphoblastic leukemia; Previous treatment with CAR-T therapy, chemotherapy, and/or hematopoietic stem cell transplantation; Age between 8 and 18 years; Native Spanish speaker or high proficiency in Spanish sufficient to understand study procedures and complete assessment instruments; Access to a computer, tablet, or smartphone with an Internet connection.
Exclusion: Diagnosis of intellectual disability, autism spectrum disorder, or acquired brain injury; Presence of uncontrolled or unstable medical or psychiatric conditions unrelated to leukemia.